This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameDoxifluridine
Accession NumberDB12947
TypeSmall Molecule
GroupsInvestigational
Description

Doxifluridine has been investigated for the treatment of Stomach Cancer.

Structure
Thumb
SynonymsNot Available
External IDs RO 219738 / RO-219738
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIV1JK16Y2JP
CAS number3094-09-5
WeightAverage: 246.1924
Monoisotopic: 246.065199677
Chemical FormulaC9H11FN2O5
InChI KeyZWAOHEXOSAUJHY-ZIYNGMLESA-N
InChI
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-4-hydroxy-1,2-dihydropyrimidin-2-one
SMILES
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Doxifluridine.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Doxifluridine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxifluridine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Doxifluridine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Doxifluridine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Doxifluridine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Doxifluridine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxifluridine.Approved, Investigational
FingolimodDoxifluridine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Doxifluridine is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Doxifluridine is combined with GI-5005.Investigational
INGN 201The risk or severity of adverse effects can be increased when Doxifluridine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Doxifluridine is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Natalizumab.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Doxifluridine.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Doxifluridine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxifluridine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxifluridine.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Doxifluridine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Doxifluridine is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Doxifluridine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxifluridine.Approved
SRP 299The risk or severity of adverse effects can be increased when Doxifluridine is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Doxifluridine.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Doxifluridine is combined with TG4010.Investigational
TofacitinibDoxifluridine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMalignant Neoplasm of Stomach2
4CompletedSupportive CareMalignant Neoplasm of Stomach1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility5.36 mg/mLALOGPS
logP-0.82ALOGPS
logP-0.8ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)6.2ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area102.59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.55 m3·mol-1ChemAxon
Polarizability21.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.
KingdomChemical entities
Super ClassOrganic compounds
ClassNucleosides, nucleotides, and analogues
Sub Class5'-deoxyribonucleosides
Direct Parent5'-deoxyribonucleosides
Alternative ParentsGlycosylamines / Pyrimidones / Halopyrimidines / Aryl fluorides / Hydropyrimidines / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Ureas / Secondary alcohols
Substituents5'-deoxyribonucleoside / Glycosyl compound / N-glycosyl compound / Halopyrimidine / Pyrimidone / Aryl fluoride / Aryl halide / Pyrimidine / Hydropyrimidine / Heteroaromatic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorsorganofluorine compound, pyrimidine 5'-deoxyribonucleoside (CHEBI:31521 )
Drug created on October 20, 2016 19:32 / Updated on September 01, 2017 12:26